Johnson & Johnson Completes the Acquisition of V-Wave
Shots:
- Johnson & Johnson has successfully completed the acquisition V-Wave with aim to establish leadership in the cardiovascular segment to tackle heart failure
- Under US GAAP, this transaction will be treated as an asset acquisition, leading in-process R&D charge of about $600M in Q4’24. J&J projects a diluted adjusted EPS impact of roughly $0.24 in 2024 and ~$0.06 in 2025. Full-year financial outlook will be presented on Oct 15, 2024
- Now V-wave will to be part of J&J’s Medtech cardiovascular segment, where Ventura Interatrial Shunt an innovative implantable device, which holds great potential for heart failure with reduced ejection fraction (HFrEF) patients
Ref: Johnson & Johnson | Image: V-Wave
Related News: Johnson and Johnson to Acquire V-Wave, Expanding and Strengthening J&J MedTech Segment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
